BASI:NSD-Bioanalytical Systems, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 20.90

Change

-1.10 (-5.00)%

Market Cap

USD 0.18B

Volume

0.07M

Average Target Price

USD 17.00 (-18.66%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+3.89 (+0.98%)

USD58.08B 89.45 51.87
IDXX IDEXX Laboratories, Inc

+14.30 (+2.78%)

USD44.03B 76.63 56.74
DXCM DexCom, Inc

+8.39 (+2.15%)

USD37.82B 77.29 95.43
EXAS Exact Sciences Corporation

+3.38 (+2.66%)

USD21.50B N/A N/A
GH Guardant Health, Inc

+4.17 (+2.69%)

USD15.75B N/A N/A
OZON Ozon Holdings PLC

-0.39 (-0.62%)

USD12.72B N/A N/A
ICLR ICON Public Limited Company

+8.77 (+4.46%)

USD10.37B 31.94 21.83
PRAH PRA Health Sciences, Inc

+5.89 (+3.78%)

USD10.06B 51.29 25.53
NTRA Natera, Inc

+5.11 (+5.05%)

USD8.76B N/A N/A
SYNH Syneos Health, Inc

+6.25 (+7.86%)

USD8.29B 43.46 21.81

ETFs Containing BASI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.92% 92% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.92% 92% A- 93% A
Trailing 12 Months  
Capital Gain 386.05% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 386.05% 89% B+ 94% A
Trailing 5 Years  
Capital Gain 1,929.13% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,929.13% 97% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 87.77% 86% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.77% 86% B 93% A
Risk Return Profile  
Volatility (Standard Deviation) 104.67% 28% F 13% F
Risk Adjusted Return 83.85% 81% B- 89% B+
Market Capitalization 0.18B 27% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.60 44% F 21% F
Price/Book Ratio 28.39 8% F 5% F
Price / Cash Flow Ratio 141.86 10% F 4% F
EV/EBITDA 109.50 19% F 10% F
Management Effectiveness  
Return on Equity -40.67% 45% F 27% F
Return on Invested Capital -10.30% 61% D- 33% F
Return on Assets -0.84% 68% D+ 43% F
Debt to Equity Ratio 247.84% 10% F 6% F
Technical Ratios  
Short Ratio 0.53 94% A 79% C+
Short Percent 0.67% 96% A 87% B+
Beta 2.00 16% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector